{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-152292","form_type":"8-K","ticker":"SMMT","cik":"0001599298","company_name":"Summit Therapeutics Inc.","filed_at":"2024-06-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.157911+00:00","generated_at":"2026-06-01T06:48:50.287611+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ivonescimab plus chemo gets NMPA approval in China for EGFRm NSCLC; PFS HR 0.46 in HARMONi-A","bullets":["NMPA approved ivonescimab + chemo for 2L+ EGFR-mutant non-squamous NSCLC based on HARMONi-A Phase III trial sponsored by Akeso.","PFS hazard ratio 0.46 (p<0.001); median PFS 7.1 months vs 4.8 months for placebo + chemo.","ORR 50.6% vs 35.4% and DCR 93.1% vs 83.2%; OS trended positive (HR 0.72 at 10.2 mo follow-up).","Subgroup with 3rd-gen TKI: PFS HR 0.48; safety manageable — 5.6% discontinued ivonescimab due to TRAEs.","Multi-regional HARMONi trial (target 420 patients) enrolling; completion expected in H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-152292","json":"https://secwatch.observer/filing/0001193125-24-152292.json","markdown":"https://secwatch.observer/filing/0001193125-24-152292.md","text":"https://secwatch.observer/filing/0001193125-24-152292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1599298/000119312524152292/0001193125-24-152292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1599298/000119312524152292/d38200d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T06:48:50.287611+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}